Last $0.60 USD
Change Today +0.0171 / 2.95%
Volume 2.3M
IMUC On Other Exchanges
As of 8:04 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

immunocellular therapeutics (IMUC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $1.46
52 Week Low
11/7/14 - $0.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

immunocellular therapeutics (IMUC) Related Bloomberg News

View More Bloomberg News

immunocellular therapeutics (IMUC) Related Businessweek News

No Related Businessweek News Found

immunocellular therapeutics (IMUC) Details

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers, as well as ovarian, pancreatic, and breast cancers; and ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells. In addition, it has a differential immunization for antigen and antibody discovery platform for discovering monoclonal antibodies for therapeutic and diagnostic development. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

3 Employees
Last Reported Date: 03/14/14

immunocellular therapeutics (IMUC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $409.5K
Founder, Chairman, Chief Scientific Officer a...
Total Annual Compensation: $127.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $175.4K
Senior Vice President of Strategic Resources
Total Annual Compensation: $314.9K
Compensation as of Fiscal Year 2014.

immunocellular therapeutics (IMUC) Key Developments

ImmunoCellular Therapeutics Appoints Steven J. Swanson as Senior Vice President, Research to Lead Stem-to-T-Cell Program

ImmunoCellular Therapeutics, Ltd. announced the appointment of Steven J. Swanson, PhD, as Senior Vice President, Research. Dr. Swanson will lead the company's Stem-to-T-cell research program, which utilizes the patient's own hematopoietic stem cells to drive production of antigen-specific killer T-cells which then attack cancer cells. He will be responsible for all programmatic research and development, with the goal of identifying and advancing novel antigen-specific Stem-to-T-cell product candidates to the clinic. Prior to joining the company, Dr. Swanson was an independent consultant advising biopharmaceutical companies on basic immunology research, bio-analytical procedures, immunogenicity assessment, regulatory affairs and product quality. Dr. Swanson spent 15 years at Amgen as Department Head for Clinical Immunology.

ImmunoCellular Therapeutics, Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 02:00 PM

ImmunoCellular Therapeutics, Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 02:00 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Andrew Gengos, Chief Executive Officer, President and Director.

ImmunoCellular Seeks Acquisitions

ImmunoCellular Therapeutics, Ltd. (AMEX:IMUC) is seeking acquisitions. ImmunoCellular Therapeutics has filed a registration statement to raise gross proceeds of $20 million in a public offering of common stock and warrants. The net proceeds of this offering will be used to fund a phase III clinical trial for ICT-107 and for general corporate purposes, including research and development activities for our other product candidates and any future product candidates that we may develop or acquire, as well as for general and administrative purposes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUC:US $0.60 USD +0.0171

IMUC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUC.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMUC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOCELLULAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at